Correction for Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation (Proceedings of the National Academy of Sciences of the United States of America (2014) 111:12 (4536-4541) DOI: 10.1073/pnas.1402604111);Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 12, 2014, Pages 4536-4541

  Gasparini, Pierluigi ^a   Lovat, Francesca ^a   Fassan, Matteo ^a,b   Casadei, Lucia ^a   Cascione, Luciano ^a,c   Jacob, Naduparambil K ^d   Carasi, Stefania ^a   Palmieri, Dario ^a   Costinean, Stefan ^d   Shapiro, Charles L ^d   Huebner, Kay ^a   Croce, Carlo M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Hospital and University Trust   (Italy)

^c INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Gamma rays; Noncoding; RNA; TNBC

Indexed keywords

BRCA1 PROTEIN; HISTONE H2AX; HISTONE H2AX GAMMA; MESSENGER RNA; MICRORNA 155; RAD51 PROTEIN; UNCLASSIFIED DRUG; VINCULIN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; FLOW CYTOMETRY; GAMMA RADIATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINATION REPAIR; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WESTERN BLOTTING;

GAMMA-RAYS; NONCODING RNA; TNBC;

BREAST NEOPLASMS; FEMALE; HOMOLOGOUS RECOMBINATION; HUMANS; MCF-7 CELLS; MICRORNAS; MODELS, BIOLOGICAL; PROGNOSIS; RAD51 RECOMBINASE; RADIATION TOLERANCE;

EID: 84896912382     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1700727114     Document Type: Erratum

References (46)

1. Ciccia A, Elledge SJ (2010) The DNA damage response: Making it safe to play with knives. Mol Cell 40(2):179-204.
2. Farmer H, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921. (Pubitemid 40559006)
3. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193-204. (Pubitemid 351301852)
4. Nogueira A, Catarino R, Medeiros R (2011) DNA damage repair and cancer: The role of RAD51 protein and its genetic variants, DNA Repair and Human Health, ed Vengrova S (InTech, Rijeka, Croatia).
5. Thompson LH, Schild D (2001) Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 477(1-2):131-153. (Pubitemid 32480197)
6. Arnaudeau C, Lundin C, Helleday T (2001) DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 307(5): 1235-1245. (Pubitemid 33027636)
7. Daboussi F, Dumay A, Delacôte F, Lopez BS (2002) DNA double-strand break repair signalling: The case of RAD51 post-translational regulation. Cell Signal 14(12): 969-975. (Pubitemid 35279421)
8. Sargent RG, Brenneman MA, Wilson JH (1997) Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol Cell Biol 17(1):267-277. (Pubitemid 26425616)
9. Takata M, et al. (1998) Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 17(18):5497-5508. (Pubitemid 28427063)
10. Jasin M (2002) Homologous repair of DNA damage and tumorigenesis: The BRCA connection. Oncogene 21(58):8981-8993.
11. Jensen RB, Ozes A, Kim T, Estep A, Kowalczykowski SC (2013) BRCA2 is epistatic to the RAD51 paralogs in response to DNA damage. DNA Repair (Amst) 12(4):306-311.
12. Klein HL (2008) The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 7(5):686-693.
13. Tsuzuki T, et al. (1996) Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 93(13):6236-6240. (Pubitemid 26230288)
14. Davies AA, et al. (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7(2):273-282. (Pubitemid 32206495)
15. Marmorstein LY, Ouchi T, Aaronson SA (1998) The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 95(23):13869-13874. (Pubitemid 28523065)
16. Süsse S, Janz C, Janus F, Deppert W, Wiesmüller L (2000) Role of heteroduplex joints in the functional interactions between human Rad51 and wild-type p53. Oncogene 19(39):4500-4512.
17. Popova M, Henry S, Fleury F (2011) Posttranslational modifications of Rad51 protein and its direct partners: Role and effect on homologous recombination - Mediated DNA repair, DNA Repair, ed Kruman I (InTech, Rijeka, Croatia), Chap 9.
18. Slupianek A, et al. (2001) BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 8(4):795-806. (Pubitemid 33030213)
19. Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T (2012) MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 72(16):4037-4046.
20. Barbano R, et al. (2011) High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Int J Cancer 129(3):536-545.
21. Le Calvez-Kelm F, et al. (2012) RAD51 and breast cancer susceptibility: No evidence for rare variant association in the Breast Cancer Family Registry study. PLoS ONE 7(12): e52374.
22. Maacke H, et al. (2000) Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88(6):907-913.
23. Martin RW, et al. (2007) RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. Cancer Res 67(20):9658-9665. (Pubitemid 47621212)
24. Baek D, et al. (2008) The impact of microRNAs on protein output. Nature 455(7209): 64-71.
25. Bartel DP (2009) MicroRNAs: Target recognition and regulatory functions. Cell 136(2): 215-233.
26. Costinean S, et al. (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103(18): 7024-7029.
27. Valeri N, et al. (2010) Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 107(15):6982-6987.
28. Cascione L, et al. (2013) Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS ONE 8(2):e55910.
29. Lyng MB, et al. (2012) Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: A DBCG study. PLoS ONE 7(5):e36170.
30. Perou CM, et al. (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752.
31. Gasparini P, et al. (2014) MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5.
32. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I (2008) MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455(7216): 1124-1128.
33. Cancer Genome Atlas N; Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
34. Isakoff SJ (2010) Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J 16(1):53-61.
35. Liedtke C, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-1281.
36. Chabner BA, Roberts TG, Jr. (2005) Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5(1):65-72.
37. Ransburgh DJ, Chiba N, Ishioka C, Toland AE, Parvin JD (2010) Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. Cancer Res 70(3):988-995.
38. Firsanov DV, Solovjeva LV, Svetlova MP (2011) H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues. Clinical Epigenetics 2(2):283-297.
39. Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36(17): 5678-5694.
40. Mueller CR, Roskelley CD (2003) Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 5(1):45-52. (Pubitemid 36553579)
41. Turner N, Tutt A, Ashworth A (2004) Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4(10):814-819. (Pubitemid 39331153)
42. Garcia AI, et al. (2011) Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 3(5):279-290.
43. Moskwa P, et al. (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41(2):210-220.
44. Bisso A, et al. (2013) Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 12(11):1679-1687.
45. Bouwman P, Jonkers J (2012) The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 12(9):587-598.
46. Rhodes DR, et al. (2007) Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2):166-180.